Sugi Predict

Sugi Predict / Compounds / SCHEMBL599279

SCHEMBL599279

SCHEMBL599279

C[C@H]([C@H](C)O)[C@H](N)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 2/20 0.57
▸ TP53 P04637 1/20 0.45
▸ SLC1A3 P43003 3/20 0.42
▸ SLC1A2 P43004 3/20 0.42
▸ SLC1A1 P43005 2/20 0.42
▸ USP2 O75604 1/20 0.39
▸ SLCO1B1 Q9Y6L6 1/20 0.39
▸ GABRP O00591 3/20 0.33
▸ GABRD O14764 3/20 0.33
▸ GABRA1 P14867 3/20 0.33
▸ GABRB1 P18505 3/20 0.33
▸ GABRG2 P18507 3/20 0.33
▸ GABRB3 P28472 3/20 0.33
▸ GABRA5 P31644 3/20 0.33
▸ GABRA3 P34903 3/20 0.33
▸ GABRA2 P47869 3/20 0.33
▸ GABRB2 P47870 3/20 0.33
▸ GABRA4 P48169 3/20 0.33
▸ GABRE P78334 3/20 0.33
▸ GABRA6 Q16445 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14420268 1.00 SLC7A5 (0.57) SLC7A5TP53SLC1A3SLC1A2SLC1A1
SCHEMBL14420361 1.00 SLC7A5 (0.57) SLC7A5TP53SLC1A3SLC1A2SLC1A1
SCHEMBL598013 1.00 SLC7A5 (0.57) SLC7A5TP53SLC1A3SLC1A2SLC1A1
SCHEMBL52746 1.00 SLC7A5 (0.57) SLC7A5TP53SLC1A3SLC1A2SLC1A1
SCHEMBL13502497 1.00 SLC7A5 (0.57) SLC7A5TP53SLC1A3SLC1A2SLC1A1
SCHEMBL52747 1.00 SLC7A5 (0.57) SLC7A5TP53SLC1A3SLC1A2SLC1A1
SCHEMBL13502491 1.00 SLC7A5 (0.57) SLC7A5TP53SLC1A3SLC1A2SLC1A1
SCHEMBL5516743 1.00 SLC7A5 (0.57) SLC7A5TP53SLC1A3SLC1A2SLC1A1
SCHEMBL4965400 1.00 SLC7A5 (0.57) SLC7A5TP53SLC1A3SLC1A2SLC1A1
SCHEMBL3574366 1.00 SLC7A5 (0.57) SLC7A5TP53SLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1999258-A1 NOVEL ALDOLASE AND PRODUCTION PROCESS OF 4-HYDROXY-L-ISOLEUCINE Ajinomoto Co., Inc. (JP) 2008-12-10 — — EP claimed
WO-2007119575-A1 NOVEL ALDOLASE AND PRODUCTION PROCESS OF 4-HYDROXY-L-ISOLEUCINE AJINOMOTO CO., INC. (JP) 2007-10-25 — — WO claimed
WO-2006093322-A2 METHOD FOR MANUFACTURING 4-HYDROXY-L-ISOLEUCINE OR A SALT THEREOF AJINOMOTO CO., INC. (JP) 2006-09-08 — — WO claimed
EP-2066799-B1 METHOD FOR PRODUCING 4-HYDROXY-L-ISOLEUCINE AJINOMOTO KK (JP) 2013-12-11 — — EP disclosed
US-8367382-B2 Method for producing 4-hydroxy-L-isoleucine AJINOMOTO CO., INC. (JP) 2013-02-05 — — US disclosed
US-8367381-B2 Method for producing 4-hydroxy-L-isoleucine AJINOMOTO CO., INC. (JP) 2013-02-05 — — US disclosed
US-8273562-B2 Method for producing 4-hydroxy-L-isoleucine AJINOMOTO CO., INC. (JP) 2012-09-25 — — US disclosed
US-20120115203-A1 METHOD FOR PRODUCING 4-HYDROXY-L-ISOLEUCINE KODERA TOMOHIRO (JP) 2012-05-10 — — US disclosed
US-20120107884-A1 METHOD FOR PRODUCING 4-HYDROXY-L-ISOLEUCINE KODERA TOMOHIRO (JP) 2012-05-03 — — US disclosed
US-20120107883-A1 METHOD FOR PRODUCING 4-HYDROXY-L-ISOLEUCINE KODERA TOMOHIRO (JP) 2012-05-03 — — US disclosed
US-8114651-B2 Method for producing 4-hydroxy-L-isoleucine AJINOMOTO CO., INC. (JP) 2012-02-14 — — US disclosed
WO-2007107008-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF DISORDERS OF FAT METABOLISM AND OBESITY INNODIA INC. (CA) 2007-09-27 — — WO disclosed
EP-1817273-A2 METHOD FOR PREPARING DIASTEREOISOMERS OF 4-HYDROXY ISOLEUCINE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2007-08-15 — — EP disclosed
WO-2006131836-A2 COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF OBESITY AND RELATED SYNDROMES INNODIA INC. (US) 2006-12-14 — — WO disclosed
WO-2006117696-A2 DIASTEREOISOMERS OF 4-HYDROXYISOLEUCINE AND USES THEREOF INNODIA INC. (CA) 2006-11-09 — — WO disclosed
WO-2006051000-A9 METHOD FOR PREPARING DIASTEREOISOMERS OF 4-HYDROXY ISOLEUCINE CENTRE NAT RECH SCIENT (FR) 2006-10-26 — — WO disclosed
US-20060223884-A1 Compounds and compositions for use in the prevention and treatment of obesity and related syndromes INVESTISSEMENT QUEBEC (CA) 2006-10-05 — — US disclosed
WO-2006093322-A2 METHOD FOR MANUFACTURING 4-HYDROXY-L-ISOLEUCINE OR A SALT THEREOF AJINOMOTO CO., INC. (JP) 2006-09-08 — — WO disclosed
WO-2006051000-A2 METHOD FOR PREPARING DIASTEREOISOMERS OF 4-HYDROXY ISOLEUCINE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2006-05-18 — — WO disclosed
EP-1657236-A1 Method for preparing diastereoisomers of 4-hydroxy isoleucine CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2006-05-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223884-A1 Compounds and compositions for use in the prevention and treatment of obesity and related syndromes GPR119, HSD3B1, PC SLC7A5 829/4885TP53 3898/4885SLC1A3 559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.